<DOC>
	<DOCNO>NCT00977379</DOCNO>
	<brief_summary>This open-label , randomize , parallel arm study evaluate effect capecitabine administer concurrently WBRT maintenance therapy participant breast cancer newly diagnose brain metastasis . Participants randomize receive either capecitabine 10 day standard WBRT , WBRT alone . Maintenance therapy follow capecitabine another systemic therapy WBRT group .</brief_summary>
	<brief_title>A Study Whole Brain Radiation Therapy Capecitabine Breast Cancer Participants With Newly Diagnosed Brain Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Women histologically confirm breast cancer know human epidermal receptor2 ( HER2 ) hormone status Newly diagnose CNS metastasis least one brain lesion measure great equal ( &gt; /= ) 1 centimeter ( cm ) two lesion measure &gt; /= 0.5 le ( &lt; ) 1 cm long dimension Participant eligible refuse surgery stereotactic radiosurgery Eastern cooperative oncology group ( EOCG ) performance status 0 2 Prior treatment brain metastasis Leptomeningeal disease Known contraindication radiotherapy magnetic resonance imaging ( MRI ) capecitabine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>